JP2022517216A5 - - Google Patents

Info

Publication number
JP2022517216A5
JP2022517216A5 JP2021540076A JP2021540076A JP2022517216A5 JP 2022517216 A5 JP2022517216 A5 JP 2022517216A5 JP 2021540076 A JP2021540076 A JP 2021540076A JP 2021540076 A JP2021540076 A JP 2021540076A JP 2022517216 A5 JP2022517216 A5 JP 2022517216A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
fragment
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021540076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517216A (ja
Filing date
Publication date
Priority claimed from CN201910022548.9A external-priority patent/CN111423510B/zh
Application filed filed Critical
Publication of JP2022517216A publication Critical patent/JP2022517216A/ja
Publication of JP2022517216A5 publication Critical patent/JP2022517216A5/ja
Pending legal-status Critical Current

Links

JP2021540076A 2019-01-10 2020-01-10 組換え抗ヒトpd-1抗体およびその用途 Pending JP2022517216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910022548.9 2019-01-10
CN201910022548.9A CN111423510B (zh) 2019-01-10 2019-01-10 重组抗人pd-1抗体及其应用
PCT/CN2020/071353 WO2020143749A1 (zh) 2019-01-10 2020-01-10 重组抗人pd-1抗体及其应用

Publications (2)

Publication Number Publication Date
JP2022517216A JP2022517216A (ja) 2022-03-07
JP2022517216A5 true JP2022517216A5 (cg-RX-API-DMAC7.html) 2023-01-20

Family

ID=71521975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540076A Pending JP2022517216A (ja) 2019-01-10 2020-01-10 組換え抗ヒトpd-1抗体およびその用途

Country Status (8)

Country Link
US (1) US20230104769A1 (cg-RX-API-DMAC7.html)
EP (1) EP3919514A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022517216A (cg-RX-API-DMAC7.html)
KR (1) KR20210113635A (cg-RX-API-DMAC7.html)
CN (1) CN111423510B (cg-RX-API-DMAC7.html)
CA (1) CA3126302A1 (cg-RX-API-DMAC7.html)
TW (1) TW202043271A (cg-RX-API-DMAC7.html)
WO (1) WO2020143749A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022012428A1 (zh) * 2020-07-14 2022-01-20 迈威(上海)生物科技股份有限公司 抗pd-1抗体及其稳定制剂
US20250270320A1 (en) * 2020-12-10 2025-08-28 Eutilex Co., Ltd. Anti-pd-1 antibody and uses thereof
CN114907478A (zh) * 2021-02-08 2022-08-16 迈威(上海)生物科技股份有限公司 结合lag-3的抗体及其用途
CN115925954A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途
WO2025102227A1 (zh) * 2023-11-14 2025-05-22 成都盛世君联生物技术有限公司 一种抗pd-1抗体及其生物材料和产品

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
RU2722451C1 (ru) * 2015-09-29 2020-06-01 Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. Pd-1 антитела и их применение.
CN106632674B (zh) * 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
CN106699889A (zh) * 2015-11-18 2017-05-24 礼进生物医药科技(上海)有限公司 抗pd-1抗体及其治疗用途
CN109152798B (zh) * 2015-12-02 2022-10-21 斯特库比股份有限公司 特异于糖基化的pd-1的抗体及其使用方法
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
CN107446048B (zh) * 2017-09-13 2021-03-30 北京韩美药品有限公司 一种能够特异性地结合pd-1的抗体及其功能片段
CN108218988B (zh) * 2017-11-29 2019-10-11 广西医科大学 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
CA3143034A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
KR20220114063A (ko) * 2019-12-13 2022-08-17 큐진 인크. 신규한 인터루킨-15 (il-15) 융합 단백질 및 이의 용도
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof

Similar Documents

Publication Publication Date Title
KR102068600B1 (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
JP2021527431A5 (cg-RX-API-DMAC7.html)
JP7785284B2 (ja) Cd38抗体とicam1抗体およびそれらの使用
CN113454119B (zh) 抗btla抗体
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2021533726A5 (cg-RX-API-DMAC7.html)
JP2020514277A5 (cg-RX-API-DMAC7.html)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2020520370A5 (cg-RX-API-DMAC7.html)
CN110536903A (zh) 抗ox40抗体及其用途
JP2019536470A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2016536020A5 (cg-RX-API-DMAC7.html)
JP2018510617A5 (cg-RX-API-DMAC7.html)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2022553922A5 (cg-RX-API-DMAC7.html)
JP2017521054A5 (cg-RX-API-DMAC7.html)
JP2023518153A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2020513759A5 (cg-RX-API-DMAC7.html)
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)